For US Healthcare Professionals Only
Filter
Dual Inhibition of IL-17A and IL-17F with Bimekizumab Demonstrated Long-Term Safety and Efficacy in Patients with Active Psoriatic Arthritis and Prior Inadequate Response to Tumour Necrosis Factor Inhibitors
Bimekizumab Demonstrates Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Bimekizumab Maintained Stringent Clinical Responses Over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Bimekizumab Demonstrated Sustained Efficacy and Safety Across the Full Spectrum of Axial Spondyloarthritis: 3-Year Results from Two Phase 3 Studies and Their Open-Label Extension
Sustained Improvements with Bimekizumab in Pain, Morning Stiffness, Fatigue, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 3-Year Results from Two Phase 3 Studies
Bimekizumab, a Dual Inhibitor of IL-17A and IL-17F, Demonstrated Long-Term Safety and Efficacy in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: Final 3-Year Results from the Phase 3 BE OPTIMAL Study and its Open-Label Extension
Bimekizumab Demonstrated Similar Efficacy and Safety in Two Clinical Endotypes of Axial Spondyloarthritis: 1-Year Results from Two Phase 3 Trials
Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS Inactive Disease in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Trials
Inhibition of Radiographic Progression with Bimekizumab Treatment Observed in bDMARD-Naïve Patients with Active Psoriatic Arthritis at 2 Years: Results from a Phase 3 Study and Its Open-Label Extension
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
Markers of IL-17 Signalling in the Blood of Patients with Psoriatic Arthritis with Inadequate Response to Tumour Necrosis Factor Inhibitors